Modification of Epidermal Growth Factor-like Repeats Witho-Fucose
Yang Wang,Li Shao,Shaolin Shi,Reed J. Harris,Michael W. Spellman,Pamela Stanley,Robert S. Haltiwanger
DOI: https://doi.org/10.1074/jbc.m107849200
IF: 5.485
2001-01-01
Journal of Biological Chemistry
Abstract:The O-fucose modification is found on epidermal growth factor-like repeats of a number of cell surface and secreted proteins. O-Fucose glycans play important roles in ligand-induced receptor signaling. For example, elongation of O-fucose on Notch by the β1,3-N-acetylglucosaminyltransferase Fringe modulates the ability of Notch to respond to its ligands. The enzyme that addsO-fucose to epidermal growth factor-like repeats, GDP-fucose protein O-fucosyltransferase (O-FucT-1), was purified previously from Chinese hamster ovary (CHO) cells. Here we report the isolation of a cDNA that encodes human O-FucT-1. A probe deduced from N-terminal sequence analysis of purified CHOO-FucT-1 was used to screen a human heart cDNA library and expressed sequence tag and genomic data bases. The cDNA contains an open reading frame encoding a protein of 388 amino acids with a predicted N-terminal transmembrane sequence typical of a type II membrane orientation. Likewise, the mouse homolog obtained from an expressed sequence tag and 5′-rapid amplification of cDNA ends of a mouse liver cDNA library encodes a type II transmembrane protein of 393 amino acids with 90.4% identity to humanO-FucT-1. Homologs were also found inDrosophila and Caenorhabditis elegans with 41.2 and 29.4% identity to human O-FucT-1, respectively. The human gene (POFUT1) is on chromosome 20 betweenPLAGL2 and KIF3B, near the centromere at 20p11. The mouse gene (Pofut1) maps near Plagl2 on a homologous region of mouse chromosome 2. POFUT1 gene transcripts were expressed in all tissues examined, consistent with the widespread localization of the modification. Expression of a soluble form of human O-FucT-1 in insect cells yielded a protein of the predicted molecular weight with O-FucT-1 kinetic and enzymatic properties similar to those of O-FucT-1 purified from CHO cells. The identification of the gene encoding proteinO-fucosyltransferase I now makes possible mutational strategies to examine the functions of the unusual O-fucose post-translational modification. The O-fucose modification is found on epidermal growth factor-like repeats of a number of cell surface and secreted proteins. O-Fucose glycans play important roles in ligand-induced receptor signaling. For example, elongation of O-fucose on Notch by the β1,3-N-acetylglucosaminyltransferase Fringe modulates the ability of Notch to respond to its ligands. The enzyme that addsO-fucose to epidermal growth factor-like repeats, GDP-fucose protein O-fucosyltransferase (O-FucT-1), was purified previously from Chinese hamster ovary (CHO) cells. Here we report the isolation of a cDNA that encodes human O-FucT-1. A probe deduced from N-terminal sequence analysis of purified CHOO-FucT-1 was used to screen a human heart cDNA library and expressed sequence tag and genomic data bases. The cDNA contains an open reading frame encoding a protein of 388 amino acids with a predicted N-terminal transmembrane sequence typical of a type II membrane orientation. Likewise, the mouse homolog obtained from an expressed sequence tag and 5′-rapid amplification of cDNA ends of a mouse liver cDNA library encodes a type II transmembrane protein of 393 amino acids with 90.4% identity to humanO-FucT-1. Homologs were also found inDrosophila and Caenorhabditis elegans with 41.2 and 29.4% identity to human O-FucT-1, respectively. The human gene (POFUT1) is on chromosome 20 betweenPLAGL2 and KIF3B, near the centromere at 20p11. The mouse gene (Pofut1) maps near Plagl2 on a homologous region of mouse chromosome 2. POFUT1 gene transcripts were expressed in all tissues examined, consistent with the widespread localization of the modification. Expression of a soluble form of human O-FucT-1 in insect cells yielded a protein of the predicted molecular weight with O-FucT-1 kinetic and enzymatic properties similar to those of O-FucT-1 purified from CHO cells. The identification of the gene encoding proteinO-fucosyltransferase I now makes possible mutational strategies to examine the functions of the unusual O-fucose post-translational modification. epidermal growth factor-like urinary-type plasminogen activator protein O-fucosyltransferase 1 Chinese hamster ovary polymerase chain reaction kilobase(s) expressed sequence tag nickel-nitrilotriacetic acid high performance liquid chromatography thrombospondin type 1 repeat The extent and variety of carbohydrate modifications found on proteins are enormous. Although historically a major focus has been on determining the structure and function of N-glycans attached to asparagine residues, our knowledge of the scope and variety of serine/threonine-linked O-glycans has expanded greatly in the last decade. In addition to the well known mucin-typeO-GalNAc and glycosaminoglycan O-xylose classes of glycans, several others have been described, includingO-GlcNAc modification of nuclear and cytoplasmic proteins (1Comer F.I. Hart G.W. J. Biol. Chem. 2000; 275: 29179-29182Abstract Full Text Full Text PDF PubMed Scopus (328) Google Scholar), O-mannose modification of brain glycoproteins (2Smalheiser N.R. Haslam S.M. Sutton-Smith M. Morris H.R. Dell A. J. Biol. Chem. 1998; 273: 23698-23703Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar), andO-glucose and O-fucose modifications of epidermal growth factor-like (EGF)1repeats (3Harris R.J. Spellman M.W. Glycobiology. 1993; 3: 219-224Crossref PubMed Scopus (222) Google Scholar). Several recent publications demonstrate that these novel forms of protein O-glycosylation play interesting and significant roles in the biological functions of the proteins they modify (4Shafi R. Iyer S.P. Ellies L.G. O'Donnell N. Marek K.W. Chui D. Hart G.W. Marth J.D. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 5735-5739Crossref PubMed Scopus (605) Google Scholar, 5Moloney D.J. Panin V.M. Johnston S.H. Chen J. Shao L. Wilson R. Wang Y. Stanley P. Irvine K.D. Haltiwanger R.S. Vogt T.F. Nature. 2000; 406: 369-375Crossref PubMed Scopus (723) Google Scholar). Fucose in O-linkage to serine or threonine was originally identified in amino acid fucosides isolated from human urine (6Hallgren P. Lundblad A. Svensson S. J. Biol. Chem. 1975; 250: 5312-5314Abstract Full Text PDF PubMed Google Scholar). The first protein reported to bear an O-fucose modification on an EGF repeat was urinary-type plasminogen activator (uPA) (7Kentzer E.J. Buko A.M. Menon G. Sarin V.K. Biochem. Biophys. Res. Commun. 1990; 171: 401-406Crossref PubMed Scopus (73) Google Scholar). Several other proteins were subsequently found to have O-fucose modifications, and comparison of the sequences surrounding modified serines or threonines led to the proposal of a consensus sequence forO-fucose modification: C2 XXGGS/TC3, where C2 and C3 are the second and third conserved cysteine residues of the EGF repeat, X is any amino acid, and S/T is the modified serine or threonine (3Harris R.J. Spellman M.W. Glycobiology. 1993; 3: 219-224Crossref PubMed Scopus (222) Google Scholar). Many proteins containing this sequence in the context of an EGF repeat have been identified in data base searches, and several of these proteins have subsequently been demonstrated to contain O-fucose residues (8Harris R.J. Van Halbeek H. Glushka J. Basa L.J. Ling V.T. Smith K.J. Spellman M.W. Biochemistry. 1993; 32: 6539-6547Crossref PubMed Scopus (96) Google Scholar, 9Moloney D.J. Haltiwanger R.S. Glycobiology. 1999; 9: 679-687Crossref PubMed Scopus (44) Google Scholar, 10Moloney D.J. Shair L. Lu F.M. Xia J. Locke R. Matta K.L. Haltiwanger R.S. J. Biol. Chem. 2000; 275: 9604-9611Abstract Full Text Full Text PDF PubMed Scopus (291) Google Scholar). O-Fucose glycans exist on glycoproteins as either a monosaccharide (Fuc-O-Ser/Thr), a tetrasaccharide (NeuAcα2, 3/6Galβ1, 4GlcNAcβ1, 3Fuc-O-Ser/Thr), or a di- or trisaccharide intermediate in tetrasaccharide biosynthesis (3Harris R.J. Spellman M.W. Glycobiology. 1993; 3: 219-224Crossref PubMed Scopus (222) Google Scholar, 5Moloney D.J. Panin V.M. Johnston S.H. Chen J. Shao L. Wilson R. Wang Y. Stanley P. Irvine K.D. Haltiwanger R.S. Vogt T.F. Nature. 2000; 406: 369-375Crossref PubMed Scopus (723) Google Scholar). Recent work from several laboratories has demonstrated a functional role for O-fucose glycans on the Notch protein. Fringe, a modulator of Notch signaling (11Irvine K.D. Curr. Opin. Genet. Dev. 1999; 9: 434-441Crossref PubMed Scopus (168) Google Scholar), is an O-fucose β1,3-N-acetylglucosaminyltransferase that extends theO-fucose moieties on Notch (5Moloney D.J. Panin V.M. Johnston S.H. Chen J. Shao L. Wilson R. Wang Y. Stanley P. Irvine K.D. Haltiwanger R.S. Vogt T.F. Nature. 2000; 406: 369-375Crossref PubMed Scopus (723) Google Scholar, 12Bruckner K. Perez L. Clausen H. Cohen S. Nature. 2000; 406: 411-415Crossref PubMed Scopus (597) Google Scholar). Elongation ofO-fucose residues on EGF repeats of Notch by Fringe modulates Notch activation by the ligands Delta and Serrate/Jagged. Fringe potentiates signaling from Delta but inhibits signaling from Serrate/Jagged (13Panin V.M. Papayannopoulos V. Wilson R. Irvine K.D. Nature. 1997; 387: 908-912Crossref PubMed Scopus (508) Google Scholar, 14Fleming R.J. Gu Y. Hukriede N.A. Development. 1997; 124: 2973-2981Crossref PubMed Google Scholar). How the elongation of O-fucose residues on Notch mediates altered signaling is not yet understood, but the β1,3-N-acetylglucosaminyltransferase activity is essential for Fringe to exert its effects on Notch (5Moloney D.J. Panin V.M. Johnston S.H. Chen J. Shao L. Wilson R. Wang Y. Stanley P. Irvine K.D. Haltiwanger R.S. Vogt T.F. Nature. 2000; 406: 369-375Crossref PubMed Scopus (723) Google Scholar, 12Bruckner K. Perez L. Clausen H. Cohen S. Nature. 2000; 406: 411-415Crossref PubMed Scopus (597) Google Scholar, 15Munro S. Freeman M. Curr. Biol. 2000; 10: 813-820Abstract Full Text Full Text PDF PubMed Scopus (165) Google Scholar). These results demonstrate that the O-fucose modification plays a key role in regulating an important signal transduction event: activation of the Notch receptor. Another signaling reaction influenced by O-fucose is that of uPA and its receptor (16Rabbani S.A. Mazar A.P. Bernier S.M. Haq M. Bolivar I. Henkin J. Goltzman D. J. Biol. Chem. 1992; 267: 14151-14156Abstract Full Text PDF PubMed Google Scholar). BecauseO-fucose exists on a number of other biologically important proteins, it may also influence their functions. The enzyme responsible for adding O-fucose to EGF repeats (GDP-fucose protein O-fucosyltransferase 1 orO-FucT-1) was originally identified and purified from Chinese hamster ovary (CHO) cells (17Wang Y. Lee G.F. Kelley R.F. Spellman M.W. Glycobiology. 1996; 6: 837-842Crossref PubMed Scopus (57) Google Scholar, 18Wang Y. Spellman M.W. J. Biol. Chem. 1998; 273: 8112-8118Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar). Interestingly,O-FucT-1 does not fucosylate synthetic peptides containing the C2 XXGGS/TC3 consensus sequence, but it does require a properly folded EGF repeat with the consensus sequence as acceptor (18Wang Y. Spellman M.W. J. Biol. Chem. 1998; 273: 8112-8118Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar). A significant fraction ofO-FucT-1 activity in CHO cells is soluble, but it appears to be a membrane-bound protein released by proteolysis as observed with many other Golgi glycosyltransferases (19Kleene R. Berger E.G. Biochim. Biophys. Acta Rev. Biomembr. 1993; 1154: 283-325Crossref PubMed Scopus (202) Google Scholar). As with most glycosyltransferases, O-FucT-1 is strongly activated by manganese. It was purified more than 5,000-fold using affinity chromatography on columns made with acceptor substrate (recombinant EGF repeat from factor VII) and donor substrate (GDP-hexanolamine-Sepharose) (18Wang Y. Spellman M.W. J. Biol. Chem. 1998; 273: 8112-8118Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar). In this paper we present the N-terminal sequence for the CHO O-FucT-1 and its use in identifying a cDNA for human O-FucT-1. Transcripts of the gene (HGNC-approved symbol: POFUT1) are expressed in all human tissues examined, and homologous genes exist in mice, Drosophila, and Caenorhabditis elegans. These results are consistent with the widespread occurrence of theO-fucose modification on proteins. CHO O-FucT-1 was purified as described (18Wang Y. Spellman M.W. J. Biol. Chem. 1998; 273: 8112-8118Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar), and 2 µg of purified enzyme was subjected to N-terminal peptide sequence analysis using a Hewlett-Packard model G1000A protein sequencer. Based on the peptide sequence of CHO O-FucT-1, a blast search was performed in GenBank (Unigene), and a human cDNA sequence, KIAA0180 (accession number D80002) was obtained which contains an open reading frame encoding a protein of 366 amino acids. PCR primers were designed based on sequences from KIAA0180: kiaa 16–55 (5′-CTTCTTGGGCTCTCTGGCATTTGCAAAGCTGCTAAACCGT-3′) and kiaa 1110–1071 (5′-GCCCTGGGATATGGAGCGTCTCCCTCCTTGAGGGGTCCCT-3′). Using a human heart cDNA library (CLONTECH) as template, a 1.1-kb PCR product was obtained. A radiolabeled probe was generated from the PCR product by random priming, and the probe was used to screen the human heart cDNA library according to the manufacturer's instructions. Recombinant λ DNA from purified positive clones was digested with EcoRI and subjected to Southern analysis. The probe for the Southern analysis was made from two partially overlapping oligonucleotides from the 5′-end of the KIAA0180 sequence (kiaa 16–55, see above, and kiaa 80–41, 5′-CAATCCAAGGAGGGACAGCCAAGGTACGGTTTAGCAGCTT-3′). The probe was filled in using Klenow fragment and 32P-labeled dNTPs.EcoRI fragments reacting with the probe were purified on agarose gels and subcloned into pBluescript II SK+ plasmid (Stratagene), and the resulting plasmids were sequenced. A clone containing the coding region of the POFUT1 gene was used for all subsequent experiments (pBS-hOFT). Additional 3′- and 5′-untranslated regions were determined by assembling overlappingPOFUT1 ESTs from dbEST and from the human genomic DNA sequence (accession number AL121897). To obtain the mouse sequence, KIAA0180 was used to search the mouse EST data base, and one EST (accession number AI664300, 460 base pairs) was found. To obtain 5′ sequence two primers (PS513, 5′-CCGTCCTCACCATCTCATCTGA-3′; and PS511, 5′-ACATGTCTTCTTATCAGGACTTCG-3′) based on this EST were used with Marathon-ready cDNA (CLONTECH) from mouse liver. From a 0.5-kb 5′-rapid amplification of cDNA ends product and the EST a 760-base pair sequence was obtained. The 3′-region was derived from mouse genomic DNA sequence (accession number AC078911) and was confirmed by reverse transcription-PCR using primers, PS598 (5′-GGGACCAGTTTCATGTGAGTTTCAATAAGTCAGA-3′) and PS599 (5′-CCACCTCTGGCAGAAAAGAAAAGGGATGTGTAAT-3′) with Marathon-ready cDNA from liver (CLONTECH) as the template. The POFUT1 coding sequence was excised from pBS-hOFT using EcoRI and labeled by random priming using the Ready-to-Go kit from Amersham Pharmacia Biotech according to the manufacturer's instructions to a specific activity of 1 × 109 cpm/µg. A human multitissue RNA blot was purchased from CLONTECH, probed, and washed under high stringency conditions according to the manufacturer's instruction for cDNA probes. Baculovirus-mediated insect cell expression was used to express a soluble form of human O-FucT-1 (amino acids 24–388) with an N-terminal His6 tag. A baculovirus transfer vector with a signal peptide was generated from pVL1392HAX (20Ruppert S. Wang E.H. Tjian R. Nature. 1993; 362: 175-179Crossref PubMed Scopus (192) Google Scholar). Two complementary oligonucleotides (RS1, 5′-CATGGCCAAGTTCCTGGTCAACGTGGCCCTGCTGCTGCTGCTGCTGCTGCTGTCCGGAGCCTGGGCCCA-3′; and RS2, 5′-TATGGGCCCAGGCTCCGGACAGCAGCAGCAGCAGCAGCAGCAGGGCCACGTTGACCAGGAACTTGGC-3′) encoding the signal sequence from honeybee melittin were generated and subcloned into the NcoI/NdeI site of pVL1392HAX. The resulting transfer vector was called pbSP. The coding sequence for the luminal domain of human POFUT1 was excised from pBS-hOFT using SacII and XbaI. Two complementary oligonucleotides (YW1, 5′-TGGGCCCATATGAGATCCCATCACCATCACCATCACATGCCCGCGGGCTCC-3′; and YW2, 5′-GGAGCCCGCGGGCATGTGATGGTGATGGTGATGGGATCTCATATGGGCCCA-3′) encoding NdeI and SacII sites and the His6 sequence was used as linker for the cDNA and vector. The baculovirus transfer vector (pbSP) was cut withNdeI and SpeI (compatible with XbaI). A triple ligation was performed with pbSP, the excised cDNA, and the His6-encoding linker, and the resulting plasmid was transfected into Sf9 cells using the BaculoGold expression kit (Pharmingen). Recombinant viral clones were plaque purified three times. Viral stocks of 108 plaque-forming units/ml were prepared by repeated amplification. The protein was expressed by infecting 2 × 107 Sf9 cells with 5 × 108 plaque-forming units of recombinant virus. Medium was collected 72 h after infection, clarified by centrifugation, dialyzed against 20 mm Tris-HCl, pH 8.0, and loaded onto a 0.5-ml Ni2+-NTA-agarose column (Qiagen). The column was washed with 4 ml of 0.1 m Tris-HCl, pH 8.0, 0.5m NaCl and eluted sequentially with 2 ml of 25 mm imidazole HCl, pH 7.0, 0.5 m NaCl followed by 3 ml of 0.5 m imidazole HCl, pH 7.0. Each fraction was subjected to SDS-polyacrylamide gel electrophoresis, stained with silver and assayed for enzyme activity. O-FucT-1 activity was assayed using GDP-[3H]fucose and recombinant His6-tagged factor VII EGF domain as described (17Wang Y. Lee G.F. Kelley R.F. Spellman M.W. Glycobiology. 1996; 6: 837-842Crossref PubMed Scopus (57) Google Scholar). All assays were performed as duplicates. N-terminal sequence analysis was performed on the purified protein as described above. Product analysis (reverse phase HPLC, β-elimination ofO-linked sugars, gel filtration using a Superdex column, and high pH anion exchange chromatographic analysis on a Dionex MA1 column) of fucosylated EGF repeat was performed as described (10Moloney D.J. Shair L. Lu F.M. Xia J. Locke R. Matta K.L. Haltiwanger R.S. J. Biol. Chem. 2000; 275: 9604-9611Abstract Full Text Full Text PDF PubMed Scopus (291) Google Scholar). O-FucT-1 was purified from CHO cells as described (18Wang Y. Spellman M.W. J. Biol. Chem. 1998; 273: 8112-8118Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar) and subjected to N-terminal sequencing. The N-terminal peptide sequence of 61 amino acids was obtained: RLAGSWDLAGYLLYXPXMGRFGNQADHFLGSLAFAKLXVRTLAVPPWIEYQHHKPPFTNLH, where cycles that yielded uncertain residues are marked asX. Blast searches with the sequence above revealed a cDNA, KIAA0180 (accession number D80002), coding for a 366-amino acid protein of unknown function from the human myeloblast cell line KG-1. Mammalian glycosyltransferases are typically type II transmembrane proteins (19Kleene R. Berger E.G. Biochim. Biophys. Acta Rev. Biomembr. 1993; 1154: 283-325Crossref PubMed Scopus (202) Google Scholar, 21Paulson J.C. Colley K.J. J. Biol. Chem. 1989; 264: 17615-17618Abstract Full Text PDF PubMed Google Scholar), but computer analysis failed to find a transmembrane domain near the N terminus of the predicted human protein. To obtain a clone with a complete open reading frame, a human heart cDNA library was screened. Initially, a PCR fragment was obtained from the library using kiaa 16–55 and kiaa 1110–1071 as primers, and a probe was made from the PCR fragment using the random priming method. The human heart cDNA library was screened using this probe, and a number of clones were identified. DNA sequencing confirmed that they contained the KIAA0180 sequence with varying 5′-extensions. One clone extended the open reading frame upstream to an “ATG” that results in a protein with a classic type II transmembrane domain (accession number for cDNA AF375884). This 5′-sequence is present in the human genomic DNA sequence (accession number AL121897). Additional cDNA sequence including 3′- and 5′-untranslated regions were determined by assembling overlappingPOFUT1 ESTs from dbEST and from the human genome sequence. The human POFUT1 cDNA encodes a protein of 388 amino acids with a predicted type II transmembrane organization (Fig.1, accession number AF375884). The N-terminal sequence obtained from CHO O-FucT-1 begins at the end of the predicted transmembrane domain, suggesting that during purification, CHO O-FucT-1 was proteolyzed, as is typical of many glycosyltransferases, and consistent with the solubility properties of CHO O-FucT-1 (17Wang Y. Lee G.F. Kelley R.F. Spellman M.W. Glycobiology. 1996; 6: 837-842Crossref PubMed Scopus (57) Google Scholar, 18Wang Y. Spellman M.W. J. Biol. Chem. 1998; 273: 8112-8118Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar). The cDNA also contains an extensive 3′-untranslated region, typical of many glycosyltransferases (22Breton C. Imberty A. Curr. Opin. Struct. Biol. 1999; 9: 563-571Crossref PubMed Scopus (171) Google Scholar). Two potential polyadenylation signals were found, providing an explanation for the existence of a doublet by Northern analysis (see below). To obtain a mouse POFUT1 cDNA sequence, KIAA0180 was used to search the mouse EST data base, and one EST (accession numberAI664300, 460 base pairs) was found. Two primers based on this EST sequence, PS513 and PS511, were used to amplify the 5′-region with Marathon-ready cDNA from mouse liver. By assembling the 0.5-kb PCR product and the EST, a 760-base pair sequence that encodes the N-terminal region of a protein with a typical type II transmembrane domain was obtained. The remaining 3′-coding sequence of mousePOFUT1 was derived from mouse genomic DNA sequence (accession number AC078911) and was confirmed by PCR using PS598 and PS599 with Marathon-ready cDNA from mouse liver. 15 nucleotide discrepancies between the cDNA sequence and the genomic DNA sequence included 7 that give amino acid changes. All 7 amino acid residues in the mouse cDNA are identical to the equivalent residue in the human POFUT1 sequence. The mouse POFUT1cDNA encodes a protein of 393 amino acids with a type II transmembrane domain (accession number AF375885). The full-length amino acid sequence of human O-FucT-1 was used to search the Drosophila and C. elegans data bases, and a related gene is present in both organisms (accession number AAF58290.1 for Drosophila and T15511 for C. elegans). The C. elegans POFUT1 gene includes 109 extra amino acids at the N terminus, which derives from three 5′-exons predicted by computer algorithm. These 109 amino acids represent an unusually long cytoplasmic domain for a glycosyltransferase and may or may not be present in the C. elegans O-FucT-1. NoPOFUT1 gene homologs were found in yeast or prokaryotes. Human and mouse O-FucT-1 are both type II transmembrane proteins and share a high level of identity (90.4%) (Fig.2), whereas the Drosophila andC. elegans homologs show 41.2 and 29.4% identity with humanO-FucT-1, respectively. Six cysteines and one potentialN-glycan consensus site are conserved, as well as the majority of aromatic residues. The CHO O-FucT-1 is known to be N-glycosylated (18Wang Y. Spellman M.W. J. Biol. Chem. 1998; 273: 8112-8118Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar), suggesting that valine in the CHO sequence at the predicted N-glycosylation site (Fig. 2) is probably the result of a sequencing error. A conserved DXD-like motif (ERD, see Fig. 2), found in many classes of glycosyltransferase (23Wiggins C.A.R. Munro S. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 7945-7950Crossref PubMed Scopus (321) Google Scholar), is located near the C terminus. Comparison of the humanPOFUT1 cDNA coding sequence with the genomic DNA sequence (accession number AL121897) revealed that humanPOFUT1 is organized into 7 exons (Fig.3A). The boundary sequences of the six exon/intron junctions are shown in Fig. 3 B. Previous analysis of the KIAA0180 sequence mapped it to human chromosome 20 ((24Kikuno R. Nagase T. Suyama M. Waki M. Hirosawa M. Ohara O. Nucleic Acids Res. 2000; 28: 331-332Crossref PubMed Scopus (42) Google Scholar), www.kazusa.or.jp/huge/gfpage/KIAA0180/), and analysis of the BAC clone RP11-392M18 (accession number AL121897) shows thatPOFUT1 lies between PLAGL2 and KIF3B, close to the centromere of chromosome 20 at 20q11. The mousePofut1 gene has the same exon/intron organization as the human gene (data not shown), whereas the Drosophila andC. elegans Pofut1-related genes are organized differently (data not shown). Analysis of the BAC clone RP23-111A22 (accession number AC078911) from mouse chromosome 2 reveals thatPofut1 lies adjacent to Plagl2 in a region homologous with human chromosome 20. The mouse BAC clone terminates before the Kif3B gene predicted to followPofut1. Northern analysis showed major transcripts from the POFUT1 gene of ∼5 kb expressed at high levels in all human tissues examined (Fig.4). Several other weaker bands also hybridized, suggesting that there may be other transcripts expressed in some tissues. Previous analysis of the expression pattern of KIAA0180 ((22), www.kazusa.or.jp/huge/gfpage/KIAA0180/) showed a similar pattern of expression in spleen, thymus, prostate, testis, ovary, small intestine, colon, and peripheral blood leukocytes. They also showed resolution of the major transcripts into two species of ∼4.8 and 5.4 kb, consistent with the sizes predicted from the cDNA sequence using the two polyadenylation signals identified in the 3′-untranslated region (Fig. 1). To demonstrate that the cloned POFUT1 cDNA encodes a protein withO-FucT-1 activity, a partial POFUT1 cDNA encoding the predicted O-FucT-1 luminal domain (amino acids 24–388, lacking the transmembrane domain) was cloned into a baculoviral expression plasmid containing an N-terminal signal sequence and His6 tag for expression in insect cells (Fig.5A). Sf9 cells were infected with recombinant virus, and the His6-tagged humanO-FucT-1 was purified from the medium using Ni2+-NTA-agarose. Fractions from the purification were analyzed by SDS-polyacrylamide gel electrophoresis (Fig. 5 B) and for O-FucT-1 enzymatic activity (Fig. 5 C). The activity bound to the Ni2+-NTA-agarose column and eluted with imidazole. A 43-kDa protein coeluted with the activity (Fig. 5 B), in agreement with the predicted size of truncatedO-FucT-1. Amino terminal sequence analysis of the purified protein gave:XXRSHHHHHHMPAGSWDPAGYLLYXPXMGR, confirming that the expressed protein was the His6-tagged recombinant human O-FucT-1. Product characterization demonstrated that the secretedO-fucosyltransferase generated the correct product. Reverse phase HPLC analysis of 3H-fucosylated product showed that the radioactivity migrated exclusively with the factor VII EGF repeat (Fig. 6A), demonstrating that the [3H]fucose was covalently associated with the EGF repeat. The [3H]fucose was released from the EGF repeat by alkali-induced β-elimination forming the monosaccharide [3H]fucitol (Fig. 6, B and C), the expected product from the β-elimination of O-fucose in the presence of sodium borohydride. These results demonstrate that recombinant O-FucT-1 adds O-fucose to factor VII EGF repeat. To compare recombinant human O-FucT-1 with the purified CHO O-FucT-1 further, the dependence of activity on protein and substrate concentrations was examined (Fig.7). The kinetic parameters of human O-FucT-1 for the substrates factor VII EGF repeat and GDP-fucose compare favorably with the published values for purified CHOO-FucT-1. The Km obtained for factor VII EGF was 6 µm compared with 11 µm for CHO O-FucT-1 (18Wang Y. Spellman M.W. J. Biol. Chem. 1998; 273: 8112-8118Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar), and for GDP-fucose, theKm was 4 µm compared with 5.9–6.4 µm for CHO O-FucT-1 (18Wang Y. Spellman M.W. J. Biol. Chem. 1998; 273: 8112-8118Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar). TheV max for recombinant human O-FucT-1 was 3 µmol/min·mg compared with 2.5 µmol/min·mg for CHOO-FucT-1 (18Wang Y. Spellman M.W. J. Biol. Chem. 1998; 273: 8112-8118Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar). As noted for purified CHO O-FucT-1 (18Wang Y. Spellman M.W. J. Biol. Chem. 1998; 273: 8112-8118Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar), high concentrations of EGF repeat caused inhibition of fucose transfer by human O-FucT-1 (data not shown). In addition, human O-FucT-1 was inhibited by EDTA (data not shown), consistent with the manganese requirement of CHO O-FucT-1 activity (18Wang Y. Spellman M.W. J. Biol. Chem. 1998; 273: 8112-8118Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar). These results demonstrate that the clonedPOFUT1 cDNA encodes the O-FucT-1 glycosyltransferase. The O-fucose modification has been found on proteins from a wide variety of species, ranging from humans to fruit flies (3Harris R.J. Spellman M.W. Glycobiology. 1993; 3: 219-224Crossref PubMed Scopus (222) Google Scholar,5Moloney D.J. Panin V.M. Johnston S.H. Chen J. Shao L. Wilson R. Wang Y. Stanley P. Irvine K.D. Haltiwanger R.S. Vogt T.F. Nature. 2000; 406: 369-375Crossref PubMed Scopus (723) Google Scholar), and a protein O-fucosyltransferase that generates the modification has been purified from CHO cells (18Wang Y. Spellman M.W. J. Biol. Chem. 1998; 273: 8112-8118Abstract Full Text Full Text PDF PubMed Scopus (97) Google Scholar). In this paper we report the sequences of human and mouse cDNAs that encodeO-FucT-1 and the organization of the human POFUT1gene. The POFUT1 gene sequence is highly conserved in mammals and is also present in Drosophila and C. elegans. The gene is expressed in all mammalian tissues examined, suggesting that the O-fucose modification may play biological roles in different contexts. O-FucT-1 has a predicted type II transmembrane structure, consistent with the domain organization of nearly all known mammalian Golgi glycosyltransferases (19Kleene R. Berger E.G. Biochim. Biophys. Acta Rev. Biomembr. 1993; 1154: 283-325Crossref PubMed Scopus (202) Google Scholar, 21Paulson J.C. Colley K.J. J. Biol. Chem. 1989; 264: 17615-17618Abstract Full Text PDF PubMed Google Scholar) and the membrane association data of the enzyme (17Wang Y. Lee G.F. Kelley R.F. Spellman M.W. Glycobiology. 1996; 6: 837-842Crossref PubMed Scopus (57) Google Scholar).O-FucT-1 does not share any obvious sequence similarity with any other class of glycosyltransferases, including the α1,2, α1,3/4, or α1,6-fucosyltransferases (22Breton C. Imberty A. Curr. Opin. Struct. Biol. 1999; 9: 563-571Crossref PubMed Scopus (171) Google Scholar). Six highly conserved cysteines are present in O-FucT-1 as well as a DXD-like motif (ERD), conserved in mammals,Drosophila, and C. elegans. Both features are characteristic of several glycosyltransferase families (22Breton C. Imberty A. Curr. Opin. Struct. Biol. 1999; 9: 563-571Crossref PubMed Scopus (171) Google Scholar, 23Wiggins C.A.R. Munro S. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 7945-7950Crossref PubMed Scopus (321) Google Scholar). Only one homologous gene has been identified for each species. The presence of O-fucose on EGF repeats is known to play a critical role in signal transduction through two distinct pathways. Binding of uPA to the uPA receptor is mediated through the EGF repeat of uPA (16Rabbani S.A. Mazar A.P. Bernier S.M. Haq M. Bolivar I. Henkin J. Goltzman D. J. Biol. Chem. 1992; 267: 14151-14156Abstract Full Text PDF PubMed Google Scholar, 25Appella E. Robinson E.A. Ullrich S.J. Stoppelli M.P. Corti A. Cassini G. Blasi F. J. Biol. Chem. 1987; 262: 4437-4440Abstract Full Text PDF PubMed Google Scholar). Removal of O-fucose from the EGF repeat has no effect on binding to the uPA receptor, but bound, unfucosylated EGF repeat does not activate the receptor. Thus, the O-fucose modification is not required for binding, but it plays an essential role in activation of the uPA receptor. The details of howO-fucose mediates this effect are not understood, but it is known that the addition of O-fucose to an EGF repeat does not significantly alter the conformation of the polypeptide chain. Using NMR, Kao and co-workers (26Kao Y.-H. Lee G.F. Wang Y. Starovasnik M.A. Kelley R.F. Spellman M.W. Lerner L. Biochemistry. 1999; 38: 7097-7110Crossref PubMed Scopus (36) Google Scholar) examined the structure of the factor VII EGF repeat with and without an O-fucose. The presence of the O-fucose had very little effect on the tertiary structure of the EGF repeat, but it did form a significant knob-like feature on one face of the module. Thus, modification of the protein with O-fucose would not be predicted to cause a conformational change in the protein, but it could certainly affect the interactions of the EGF repeat with other molecules. In the Notch signaling pathway, O-fucose also plays a key role in receptor activation. O-Fucose serves as an acceptor for Fringe, a β1,3-N-acetylglucosaminyltransferase, resulting in the elongation of the O-fucose monosaccharide into a tetrasaccharide on EGF repeats of Notch (5Moloney D.J. Panin V.M. Johnston S.H. Chen J. Shao L. Wilson R. Wang Y. Stanley P. Irvine K.D. Haltiwanger R.S. Vogt T.F. Nature. 2000; 406: 369-375Crossref PubMed Scopus (723) Google Scholar, 12Bruckner K. Perez L. Clausen H. Cohen S. Nature. 2000; 406: 411-415Crossref PubMed Scopus (597) Google Scholar). This alteration in the carbohydrate structure somehow modulates receptor activation. Interestingly, the activation of Notch can be either potentiated or inhibited, depending on the ligand (13Panin V.M. Papayannopoulos V. Wilson R. Irvine K.D. Nature. 1997; 387: 908-912Crossref PubMed Scopus (508) Google Scholar, 14Fleming R.J. Gu Y. Hukriede N.A. Development. 1997; 124: 2973-2981Crossref PubMed Google Scholar). Again, it is unlikely that the change in sugar structure alters the conformation of the individual EGF repeat, but such a change could certainly affect the ability of the modified EGF repeat to interact with ligands, other proteins, or even other portions of the Notch protein itself. Recently the presence of O-fucose in a different protein context was reported (27Hofsteenge J. Huwiler K.G. Macek B. Hess D. Lawler J. Mosher D.F. Peter-Katalinic J. J. Biol. Chem. 2001; 276: 6485-6498Abstract Full Text Full Text PDF PubMed Scopus (211) Google Scholar). Hofsteenge and co-workers showed the presence of the disaccharide Glc-Fuc O-linked to serines and threonines within the three thrombospondin type 1 repeats (TSR) of human thrombospondin-1. By comparing the sequence contexts surrounding the modified residues in each TSR they proposed the consensus sequence, CSX S/TCG, where S/T is the modified residue. AnO-linked Glcβ1,3Fuc modification of proteins in CHO cells has also been described (28Moloney D.J. Lin A.I. Haltiwanger R.S. J. Biol. Chem. 1997; 272: 19046-19050Abstract Full Text Full Text PDF PubMed Scopus (50) Google Scholar), although CHO proteins with this modification were not identified. The results of Hofsteenge and co-workers suggest that two separate O-fucose pathways exist: one modifying EGF repeats, and the other modifying TSRs. Elongation of O-fucose occurs in both pathways, but the elongation does not appear to overlap. O-Fucose on EGF repeats can be modified by a β1,3-linked GlcNAc, catalyzed by Fringe (5Moloney D.J. Panin V.M. Johnston S.H. Chen J. Shao L. Wilson R. Wang Y. Stanley P. Irvine K.D. Haltiwanger R.S. Vogt T.F. Nature. 2000; 406: 369-375Crossref PubMed Scopus (723) Google Scholar, 12Bruckner K. Perez L. Clausen H. Cohen S. Nature. 2000; 406: 411-415Crossref PubMed Scopus (597) Google Scholar), whereas O-fucose on TSRs appears to be elongated by a β1,3-linked Glc (27Hofsteenge J. Huwiler K.G. Macek B. Hess D. Lawler J. Mosher D.F. Peter-Katalinic J. J. Biol. Chem. 2001; 276: 6485-6498Abstract Full Text Full Text PDF PubMed Scopus (211) Google Scholar). An enzymatic activity capable of addition of Glc in a β1,3-linkage to fucose has been described (9Moloney D.J. Haltiwanger R.S. Glycobiology. 1999; 9: 679-687Crossref PubMed Scopus (44) Google Scholar). Interestingly, the β1,3-glucosyltransferase would not useO-fucose attached to an EGF repeat as a substrate under various conditions tested, 2D. J. Moloney and R. S. Haltiwanger, unpublished observation.suggesting that the addition of the Glc to fucose occurs only when the fucose is in a particular protein context such as a TSR. The region of thrombospondin-1 modified with the Glc-Fuc disaccharide binds to heparin and appears to be involved in a number of biologically important interactions (29Adams J.C. Tucker R.P. Dev. Dyn. 2000; 218: 280-299Crossref PubMed Scopus (265) Google Scholar), raising the interesting possibility that this class of O-fucose modifications may modulate biological events in a manner similar to O-fucose on the Notch receptor. The importance of fucose modifications on proteins has been highlighted recently by the description of the disease leukocyte adhesion deficiency type II (30Becker D.J. Lowe J.B. Biochim. Biophys. Acta. 1999; 1455: 193-204Crossref PubMed Scopus (94) Google Scholar). Patients with this disorder have reduced levels of fucose on proteins. The underfucosylation is caused by defects in the GDP-fucose transporter resulting in inefficient transport of GDP-fucose into the Golgi apparatus (31Lubke T. Marquardt T. von Figura K. Korner C. J. Biol. Chem. 1999; 274: 25986-25989Abstract Full Text Full Text PDF PubMed Scopus (119) Google Scholar, 32Luhn K. Wild M.K. Eckhardt M. Gerardy-Schahn R. Vestweber D. Nat. Genet. 2001; 28: 69-72Crossref PubMed Scopus (289) Google Scholar). The patients suffer from a wide variety of developmental and pathological problems (30Becker D.J. Lowe J.B. Biochim. Biophys. Acta. 1999; 1455: 193-204Crossref PubMed Scopus (94) Google Scholar). As the name of the disorder implies, they have a defect in recruitment of leukocytes to sites of inflammation, resulting in severe recurring bacterial infections. Leukocytes are recruited to sites of inflammation by recognition of specific fucose-containing oligosaccharide structures on their surfaces, and reduced levels of fucose impair efficient recruitment (33McEver R.P. Glycoconjugate J. 1997; 14: 585-591Crossref PubMed Scopus (240) Google Scholar). In addition to recurrent infections, these patients suffer from developmental abnormalities. They are short in stature, have unusual facial and skeletal abnormalities, and are severely mentally retarded. Because Notch receptors play key roles in numerous developmental events (34Artavanis-Tsakonas S. Rand M.D. Lake R.J. Science. 1999; 284: 770-776Crossref PubMed Scopus (4951) Google Scholar), it may be that several of the other features of leukocyte adhesion deficiency type II can be explained by defects in Notch function.